PharmaMar has reported data for a trial of Yondelis in soft tissue sarcoma (STS). The trial, known as STS-201, compares the efficacy of two dosing schedules of Yondelis (24-hour and weekly) in STS patients who have failed to respond to prior available therapies. Enrollment of 270 patients was completed during the second quarter of 2005.
The study concluded that the 24-hour dosing regime provides an added advantage to patients. In addition, no unexpected toxicities were identified in this trial.
Yondelis is an antitumor drug derived from the marine organism Ecteinascidia turbinate -- a "'sea squirt," or tunicate -- found in the Caribbean and Mediterranean seas.